Semaglutide — better known by its brand names Ozempic (for diabetes) and Wegovy (for weight loss) — received FDA approval in 2017. Since then, U.S. prescriptions have surged from roughly 6.1 billion ...

Note: Compounded drugs are not approved by theU.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. Despite new rules limiting their manufacture, compounded ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. In April 2025, the U.S. Food and Drug Administration ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. Just a few years ago, the term “GLP-1” would have been ...

Trends shaping GLP-1 landscape include FDA regulatory updates, rapid oral drug adoption, and shifting clinical evidence for diabetes care.

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Jan 12 (Reuters) - Novo Nordisk ‌CEO Mike Doustdar said on Monday as ‌many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, ...